XTL Biopharmaceuticals Ltd.
XTL Biopharmaceuticals Ltd. (XTLB) Revenue
Annual & quarterly revenue history · segment & region breakdown
XTLB · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsXTL Biopharmaceuticals Ltd. trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from $0.00B in FY2024.
Revenue trend
2024 – 2005 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2024-12-31 | $0.00B | +$0.00B | — |
| 2023-12-31 | $0.00B | +$0.00B | — |
| 2022-12-31 | $0.00B | +$0.00B | — |
| 2021-12-31 | $0.00B | +$0.00B | — |
| 2020-12-31 | $0.00B | +$0.00B | — |
| 2019-12-31 | $0.00B | +$0.00B | — |
| 2018-12-31 | $0.00B | +$0.00B | — |
| 2017-12-31 | $0.00B | +$0.00B | — |
| 2016-12-31 | $0.00B | +$0.00B | — |
| 2015-12-31 | $0.00B | +$0.00B | — |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income XTL Biopharmaceuticals Ltd. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
XTL Biopharmaceuticals Ltd. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from XTL Biopharmaceuticals Ltd.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
XTLB revenue · 4 questionsXTLB's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from $0.00B in FY2024.
▸ Source: FMP · XTL Biopharmaceuticals Ltd. SEC filings · GAAP · XTL Biopharmaceuticals Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026